Cognitive behavioral therapy
Introduction
Nonsuicidal self-injury (NSSI) behaviors are a major public health problem and have been reported by clinicians for centuries [1] . Historically, multiple terms were used to describe NSSI, including "deliberate self-harm (DSH)" ,"parasuicide behavior", "self-injurious behavior (SIB)", "self-mutilation", and "self-wounding", and uses of each of the these terms have included both NSSI and self-injury with suicidal intent [2] . NSSI is described as repeated cutting, burning, hitting, rubbing, or otherwise deliberately inflicting damage to body tissue for nonsocially sanctioned reasons, but not as a suicide attempt, and it does not include body manipulations for body adornment (e.g., tattoos or piercings). As these behaviors are often preceded by emotional distress and followed by subjective relief, NSSI is hypothesized to function as a maladaptive attempt to relieve dysphoric affect that might have an addictive or compulsive quality. The most commonly reported reason for NSSI is "to feel anything at all, even pain"; other reasons include "to try to get a reaction from someone, even if it is negative", "to stop bad feelings" or "to get control of the situation" [3] . The injury is most often inflicted with a sharp object; the resulting cuts bleed and leave a characteristic pattern of scars. Common sites for NSSI are the dorsal side of forearm and anterior area of thighs, but any body part may be a target.
Among clinical inpatient samples, estimated prevalence of NSSI is about 21 % for adults [4] and up to 40 % in adolescents [5] . In community samples, up to 6 % of adults [6•] and 35 % of adolescents [7] engage in NSSI. The onset of NSSI is commonly between 12 and 16 years of age [6•, 8] . While NSSI is more prevalent among females in adolescence [9] , no gender separation is observed in adult community [10] and clinical [11] samples.
Until recently, unified diagnostic criteria for NSSI did not exist, thus research focused on DSH or SIB did not always differentiate between suicidal and nonsuicidal intent. The Diagnostic and Statistical Manual-5 (DSM-5) released in May 2013 [12] provided for the first time a concise definition of NSSI. NSSI is included in the "Conditions for Further Study" section of DSM-5, specifying that while proposed criteria are not intended for clinical use, further research on the topic is encouraged.
NSSI, DSM-5 criteria A. In the last year, the individual has, on 5 or more days, engaged in intentional self-inflicted damage to the surface of his or her body, of a sort likely to induce bleeding or bruising or pain (e.g., cutting, burning, stabbing, hitting, excessive rubbing), with the expectation that the injury will lead to only minor or moderate physical harm (i.e., there is no suicidal intent). The absence of suicidal intent is either stated by the individual or can be inferred by the individual's repeated engagement in the behaviors that the individual knows, or has learned, it is not likely to result in death.
B. The individual engages in self-injurious behavior with one of more of the following expectations: to obtain relief from a negative feeling or cognitive state ; to resolve an interpersonal difficulty; to induce a state of positive feeling C. The intentional injury is associated with at least two of the following: 1. Negative feelings or thoughts, such as depression, anxiety, tension, anger, generalized distress, or selfcriticism occurring in the period immediately prior to the self-injurious act.
2. Prior to engaging in the act, a period of preoccupation with the intended behavior that is difficult to resist.
3. The urge to engage in self-injury occurs frequently, although it might not be acted upon. NSSI often co-exists with other psychopathology including mood disorders, personality disorders, and eating disorders [5] , and a is a strong predictor for future suicide attempts [13•] .
Treatment of NSSI
The goal of treatment intervention for NSSI is to eliminate self-injurious behaviors, to help control impulses to self-harm, and to prevent relapse and remission of any co-morbid psychiatric conditions. In many cases, this can be achieved only by thorough diagnosis followed by a combination of psychological and pharmacological interventions.
Assessment of NSSI is critical for understanding and treating NSSI. A comprehensive assessment of NSSI should include information on current and past NSSI behavior (types, methods, locations, precipitating factors, frequency, age of onset, severity, urges to self-injure, hospitalizations), understanding of biopsychosocial risk and protective factors for NSSI, and a thorough evaluation of suicide risk and co-morbid psychiatric disorders. Several instruments are available to assist in an assessment of NSSI, such as the Self-Injurious Thoughts and Behaviors Interview [14] , the Suicide Attempt Self-Injury Interview [15] , and the Ottawa Self-Injury Inventory [16] .
Psychosocial interventions
No randomized psychotherapy trials have examined DSM-5-defined NSSI behavior in adolescents or adults, and therapeutic programs specifically targeting NSSI are rare. Most published studies have focused on cognitive behavior and dialectical behavior therapeutic techniques in the treatment of self-harm, with or without suicidal intent.
& Cognitive behavior therapy (CBT) and its numerous variations is the most studied modality in DSH and SIB. A recent systematic review and meta-analysis of 28 studies found a highly significant effect for CBT in reducing self-harm in adults when compared to minimal treatment or treatment as usual (TAU) [17] . & CBT is a psychotherapeutic approach that addresses dysfunctional emotions and maladaptive behaviors by challenging cognitive processes. CBT uses some systematic procedures like continuously monitoring dysfunctional behaviors to increase patients' awareness of the problem and further, to help them replace maladaptive coping skills and cognitions with more adaptive ones. Certain components of CBT found useful in reducing deliberate harm include: increasing helpful beliefs, enhancing mood tolerance, changing behavior by increasing activity and improving problem-solving skills, building interpersonal skills through improving communication and improving social functioning, and incorporating relapse prevention [18] .
& Manual-Assisted Cognitive Behavioral Therapy (MACT) is a program developed for short-term therapy for adults with DSH, including suicidal behavior and NSSI [19] . This cognitive-oriented and problemfocused program consists of a maximum of six therapeutic sessions and is assisted by a detailed manual. The content of MACT involves problem identification and solving, working through advantages and disadvantages of self-harm behaviors and learning basic cognitive strategies to manage emotions and negative thinking, establishing successful coping skills and relapse prevention. In a controlled trial, the MACT program was tested versus TAU in 480 patients following episodes of DSH. While the proportion of those repeating DSH behaviors in the 12 months of the study showed no statistically significant difference between the MACT group and controls, the authors concluded that clinically meaningful findings like 50 % reduction of frequency of selfharm behaviors taken in conjunction with the economic evaluation indicated superiority of MACT over TAU in terms of cost and effectiveness combined [20] . Taylor and colleagues adapted MCAT for adolescents and developed a manualized 12-week CBT individual therapy program ("Cutting Down") including a thorough cognitivebehavioral assessment and systematic learning of motivational strategies and daily coping skills [21] . The 25 adolescents in the pilot study, which was not controlled, reported reduced NSSI after treatment, with continued reduction at a 3-month follow-up. & Dialectical Behavioral Therapy (DBT) was developed for the treatment of patients with borderline personality disorder (BPD), with a primary focus on self-harm reduction. DBT is multi-pronged approach consisting of skills-based training, individual psychotherapy, telephone calls, and consultation. DBT focus is on teaching the patient how to manage emotional distress through developing interpersonal skills, reality acceptance skills, and mastering emotional regulation. DBT and its shorter treatment duration modification (DBT-Brief) [22] have been shown to reduce effectively NSSI in adults and adolescents across various study designs, most commonly in BPD patients [23] . Modification of DBT for adolescents (DBT-A) has been examined in a study of 12 adolescents with NSSI and other BPD symptoms, and results indicated that DBT-A was helpful in reducing both NSSI and other symptoms of BPD with continued gains at 1-year follow-up [24] . This treatment modality requires highly skilled and trained therapists, and the duration and cost of treatment might be, in some cases, prohibitive for common use. & Mentalization-based treatment (MBT) has shown to be effective in reducing self-harm in adults [25] and adolescents (MBT-A) [26] with BPD in randomized controlled trials. MBT-A is a year-long, manualized, psychodynamic psychotherapy program, involving weekly, 50-min individual and monthly mentalization-based family sessions with a focus on reducing impulsivity and enhancing affect regulation. Mentalization is conceptualized as the capacity to understand actions in terms of thoughts and feelings. The ability to understand one's mental state and its enhancement has been proposed to increase self-control in individuals with affect dysregulation and impulse control problems. In the only randomized controlled trail in MBT of adolescents published to date, a recovery rate of 44 % of the MBT group compared to 17 % in the group receiving TAU was achieved [26] . The authors concluded that "positive change in mentalizing and improvement in interpersonal functioning seem to be the mediating factors in reduction in self-harm". & Problem-Solving Therapy (PST) is an individual therapy-based model, examining a person's approach to problems, including problem recognition and definition, brainstorming, and devising and continuous reviewing of the action plan. Within a PST model, NSSI is conceptualized as a dysfunctional solution to problems where improved problemsolving skills and increased problem awareness would lead to decreased reliance on NSSI as a coping mechanism. In a randomized trial of 1,094 adult patients admitted to inpatient hospitals with self-harm, only patients treated with PST who had history of SIB prior to current hospitalization were less likely to present again with SIB [27] . & Harm reduction has not been tested in controlled studies but various strategies have been anecdotally reported as potentially helpful in NSSI.
A main focus of treatment is seeking to understand the function NSSI serves for the patient and the interventions might include meditation, tapping into spirituality, and increasing patients' self-understanding [28] . & Increased physical activity. Preliminary evidence suggests that regular exercise or participation in sports might hold promise in decreasing urges to engage in NSSI in adolescents [29] .
Pharmacotherapy
Dysregulation in endogenous opioids, monoamines, and glutamate neurotransmitter systems are some of the neurobiological mechanisms suggested to be involved in the etiology of NSSI and its maintenance. While there is no Food and Drug Administration (FDA) approved treatment for NSSI, a number of agents modulating the three above-mentioned pathways have been explored. Of note, most of the trials discussed below were performed in individuals with developmental disabilities and this limitation should be taken in consideration when NSSI treatment plan is designed.
Opioid systems modulating agents
Naltrexone Naltrexone is an opioid receptor antagonist approved by the FDA for treatment of alcohol and opioid addictions. Treatment of NSSI with naltrexone is based on phenomenologic similarities of NSSI and addiction. Indeed, it has been hypothesized that the response to naltrexone may be predicted by elevated beta-endorphin levels following self-injurious behavior. Although naltrexone is the most studied pharmacotherapy for NSSI, little consensus exists as to its efficacy due to methodological inconsistencies and study design limitations. For example, a recent review of four randomized control trials (described further in the text) comparing the effects of naltrexone versus placebo in 42 adults with intellectual disabilities was unable to reach any definite conclusions regarding efficacy due to low power [30•] . The first of these trials reported that naltrexone attenuated SIB in all four participants, with 25 mg and 50 mg doses producing a statistically significant decrease in SIB [31] . The second trial included eight patients and results indicated that naltrexone was associated with significantly fewer days of high frequency self-injury and significantly more days with low frequency self-injury [32] . The third study of 26 participants found that neither single-dose (100 mg) nor long-term (50 and 150 mg) naltrexone treatment had any therapeutic effect on SIB [33] . Finally, naltrexone had clinically significant effects (≥33 % reduction) on the daily rates of three of the four participants' most severe forms of SIB, but results did not reach statistical significance in the most recent study included in the review [34] . There were very few noteworthy adverse events in any of the four trials that were reviewed. All trials were at high risk of bias and the short period of follow-up was a significant drawback in their design; the authors of the review thus concluded that there was "weak evidence in included trials that naltrexone was more effective than placebo for people with intellectual disability demonstrating SIB". Of interest, Symons and colleagues conducted a meta-analysis of 27 uncontrolled studies of naltrexone in 86 patients with mental retardation and NSSI and reported that 80 % of participants experienced a decrease in frequency or severity of NSSI behaviors following administration of naltrexone [35] .
Standard dosing 50 -100 mg/d
Contraindications Naltrexone is contraindicated in concurrent use with opioid analgesics or in patients currently dependent on opioids, including those currently maintained on opiate agonists.
Main side effects Generally well-tolerated; may cause nausea, vomiting, headache, dizziness, anxiety, and fatigue.
Special points Naltrexone can cause hepatocellular injury when given in higher doses, and it is contraindicated in acute hepatitis or liver failure.
Cost cost-effective as it is available in generic formulation

Buprenorphine
Buprenorphine is a semi-synthetic partial opioid agonist that is used to treat opioid addiction and to control moderate acute and chronic pain. A recent small and uncontrolled study suggested successful treatment of severe NSSI with buprenorphine (0.5 -6 mg/d) in six individuals [36] .
Monoamine-modulating agents
Antidepressants
The monoamine dysregulation found in NSSI prompted selective serotonin reuptake inhibitors (SSRIs) to be examined as treatments for reducing SIB, but no systematic research has been conducted on the benefits of antidepressants for the reduction of NSSI, and currently available data are mixed. A review of effectiveness of antidepressants in management of behavior problems, including but not limited to SIB, in adults with intellectual disabilities reported mixed results with more than 50 % of cases showing either no improvement or deterioration [37] . Fluoxetine has been investigated as a treatment for pathological skin picking, a condition which is possibly related to NSSI. While two controlled studies reported significant improvement of symptoms compared to placebo [38, 39] , a number of published reports failed to replicate such positive results [40, 41] . A comparison of clomipramine versus placebo in individuals with mental retardation found no statistically significant benefit for any outcome measure, including SIB rate and intensity, but clinically significant improvement in the rate and intensity of SIB was reported [42] . Available data do not support the use of antidepressants as first line of treatment for NSSI unless, perhaps, when NSSI is associated with depressive symptoms.
Glutamate modulating agents
N-acetylcysteine (NAC)
NAC is an amino acid and cysteine pro-drug which reduces synaptic release of glutamate. In the United States, NAC is available as a prescription product used in the treatment of cystic fibrosis and other chronic pulmonary conditions [43] and as an intravenous formulation used to treat acetaminophen overdose [44] . NAC is also available without prescription as an over-the-counter product in health food stores, usually promoted as improving overall mental function. Few reports have been published testing NAC for NSSI, DSH, or SIB, and results remain mixed. In a case study, Pittenger and colleagues reported decreases in self-injurious behaviors using NAC for a patient who experienced similar decreases in SIB on riluzole (another glutamate-modulating agent), but could not tolerate the sedative effect of the medication [45] . While NAC treatment produced conflicting results in trichotillomania studies [46, 47] , a recent overview published by Grant and colleagues recommended NAC as a pharmacological treatment strategy for skin-picking disorder [48] . Existing data on NAC in NSSI are limited and controversial and do not support the use of NAC as first-line treatment for NSSI. Nonetheless, NAC might improve some NSSI and its beneficial side effects profile, availability, and low cost should be taken in consideration when adjunctive medication in the armamentarium of agents used for NSSI is discussed.
Topiramate
Topiramate is an anticonvulsant medication and while its precise mechanism of action remains unknown, blockage of voltage-dependent sodium channels and antagonism the AMPA/kainate subtype of the glutamate receptor might contribute to its clinical properties. Preliminary uncontrolled data suggested that topiramate might help decrease skin picking [49, 50] , trichotillomania [51] and similar self-injurious behaviors [52] , particularly in individuals with intellectual disabilities. Existing data on topiramate in NSSI is very limited, but similarly to NAC, it should be taken into consideration when adjunctive medication for NSSI is discussed.
